Novo Nordisk’s Ozempic Successor, CagriSema, Falls Short of Weight Loss Expectations
CagriSema, Novo Nordisk’s experimental weight-loss drug, falls short of its 25% weight loss target in trials, impacting stock prices. Despite this, a significant portion of participants achieved substantial weight loss, leaving future potential still uncertain.
Novo Nordisk’s Ozempic Successor, CagriSema, Falls Short of Weight Loss Expectations Read More »